Ginkgo Bioworks (DNA) vs Monte Rosa Therapeutics (GLUE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Over five years, GLUE leads with a -52.0% price change compared with -97.6% for DNA. Monte Rosa Therapeutics is the larger company by market cap ($867.6 million vs $772.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNA | GLUE |
|---|---|---|
| Share price | $11.47 | $10.17 |
| Market cap | $772.39M | $867.64M |
| 1-day change | -7.57% | +3.04% |
| YTD return | — | -35.14% |
| 1-year return | — | +37.80% |
| 5-year return | -97.59% | -52.03% |
| EPS (TTM) | $-5.06 | $-1.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.22 | $25.77 |
| 52-week low | $5.37 | $7.44 |
| Distance from 52-week high | -37.05% | -60.54% |
| Average volume | 1.68M | 1.31M |
| Shares outstanding | 55.38M | 85.31M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
DNA vs GLUE FAQ
Which is bigger, Ginkgo Bioworks or Monte Rosa Therapeutics?
Monte Rosa Therapeutics (GLUE) is larger, with a market capitalization of $867.64M compared with $772.39M for Ginkgo Bioworks (DNA).
Are Ginkgo Bioworks and Monte Rosa Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.